Emergency coronary artery bypass graft surgery in abciximab-treated patients

This publication has 19 references indexed in Scilit:

• Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab
  The Journal of Thoracic and Cardiovascular Surgery, 1998
• Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
  New England Journal of Medicine, 1997
• Aprotinin use in patients with dialysis-dependent renal failure undergoing cardiac operations
  The Journal of Thoracic and Cardiovascular Surgery, 1996
• The impact of heparin concentration and activated clotting time monitoring on blood conservation
  The Journal of Thoracic and Cardiovascular Surgery, 1995
• Aprotinin
  Drugs, 1995
• Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)
  The American Journal of Cardiology, 1995
• Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery
  The American Journal of Cardiology, 1994
• Reporting the results of blood conservation studies: The need for uniform and comprehensive methods
  The Annals of Thoracic Surgery, 1994
• Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
  Circulation, 1994
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994